Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLR1A | O95602 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18226089 | 1.00 | POLR1A (0.39) | POLR1ACYP1A2KCNH2SLC6A2SLC6A3 | |
| SCHEMBL18225540 | 0.87 | CA12 (0.34) | CA12CA1CA2CA9 | |
| SCHEMBL167120 | 0.84 | HRH2 (0.41) | KCNH2SLC6A2SLC6A3HTTCA12 | |
| SCHEMBL167158 | 0.84 | HRH2 (0.41) | KCNH2SLC6A2SLC6A3HTTCA12 | |
| SCHEMBL167121 | 0.84 | HRH2 (0.41) | KCNH2SLC6A2SLC6A3HTTCA12 | |
| SCHEMBL24269614 | 0.84 | NPSR1 (0.41) | POLR1ACYP1A2KCNH2HTT | |
| SCHEMBL18226717 | 0.82 | BDKRB1 (0.46) | CYP1A2HTTL3MBTL1 | |
| SCHEMBL167048 | 0.82 | PDCD1 (0.40) | SLC6A2SLC6A3HTTCA12CA1 | |
| SCHEMBL166996 | 0.82 | PDCD1 (0.40) | SLC6A2SLC6A3HTTCA12CA1 | |
| SCHEMBL166995 | 0.82 | PDCD1 (0.40) | SLC6A2SLC6A3HTTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186602-B2 | Glucopyranosyl derivative and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-20210054013-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3747892-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186602-B2 | Glucopyranosyl derivative and use thereof | SLC5A1, SLC5A2, UGGT1 | POLR1A 4853/4885CYP1A2 817/4885KCNH2 1735/4885 |
| US-20210054013-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SLC5A1, SLC5A2, UGGT1 | POLR1A 4853/4885CYP1A2 817/4885KCNH2 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.